Literature DB >> 10441339

Introduction of heteroplasmic mitochondrial DNA (mtDNA) from a patient with NARP into two human rho degrees cell lines is associated either with selection and maintenance of NARP mutant mtDNA or failure to maintain mtDNA.

L Vergani1, R Rossi, C H Brierley, M Hanna, I J Holt.   

Abstract

Mitochondria from a patient heteroplasmic at nucleo-tide position 8993 of mitochondrial DNA (mtDNA) were introduced into two human tumour cell lines lacking mtDNA. The donor mitochondria contained between 85 and 95% 8993G:C mtDNA. All detectable mtDNA in the mitochondrially transformed cells contained the pathological 8993G:C mutation 3 months after transformation. These results suggest that 8993G:C mtDNA had a selective advantage over 8993T:A mtDNA in both lung carcinoma and osteo-sarcoma cell backgrounds. In contrast, two other presumed pathological mtDNA variants were lost in favour of 'wild-type' mtDNA molecules in the same lung carcinoma cell background. Taken together, these findings suggest that the transmission bias of mtDNA variants is dependent upon a combination of nuclear background and mtDNA genotype. A second phenomenon observed was a marked decrease in the growth rate of many putative transformed cell lines after 6 weeks of culturing in selective medium, and in these cell lines mtDNA was not readily detectable by Southern blotting. Restriction endonuclease analysis and sequencing of amplified mtDNA demonstrated that the slow growing cells contained little or no mtDNA. It is concluded that these cells represented transient mitochondrial transformants.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10441339     DOI: 10.1093/hmg/8.9.1751

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  8 in total

1.  Replicative advantage and tissue-specific segregation of RR mitochondrial DNA between C57BL/6 and RR heteroplasmic mice.

Authors:  K Takeda; S Takahashi; A Onishi; H Hanada; H Imai
Journal:  Genetics       Date:  2000-06       Impact factor: 4.562

Review 2.  Mitochondrial DNA damage and reactive oxygen species in neurodegenerative disease.

Authors:  Nadee Nissanka; Carlos T Moraes
Journal:  FEBS Lett       Date:  2018-01-09       Impact factor: 4.124

Review 3.  The awakening of an advanced malignant cancer: an insult to the mitochondrial genome.

Authors:  Cody C Cook; Masahiro Higuchi
Journal:  Biochim Biophys Acta       Date:  2011-09-02

Review 4.  Transmission of mitochondrial DNA diseases and ways to prevent them.

Authors:  Joanna Poulton; Marcos R Chiaratti; Flávio V Meirelles; Stephen Kennedy; Dagan Wells; Ian J Holt
Journal:  PLoS Genet       Date:  2010-08-12       Impact factor: 5.917

5.  Systematic segregation to mutant mitochondrial DNA and accompanying loss of mitochondrial DNA in human NT2 teratocarcinoma Cybrids.

Authors:  Carrie J Turner; Caroline Granycome; Rachel Hurst; Elizabeth Pohler; M Katariina Juhola; Martti I Juhola; Howard T Jacobs; Lesley Sutherland; Ian J Holt
Journal:  Genetics       Date:  2005-06-08       Impact factor: 4.562

6.  Mutation-specific effects in germline transmission of pathogenic mtDNA variants.

Authors:  Auke B C Otten; Suzanne C E H Sallevelt; Phillippa J Carling; Joseph C F M Dreesen; Marion Drüsedau; Sabine Spierts; Aimee D C Paulussen; Christine E M de Die-Smulders; Mary Herbert; Patrick F Chinnery; David C Samuels; Patrick Lindsey; Hubert J M Smeets
Journal:  Hum Reprod       Date:  2018-07-01       Impact factor: 6.918

Review 7.  Cytoplasmic hybrid (cybrid) cell lines as a practical model for mitochondriopathies.

Authors:  Heather M Wilkins; Steven M Carl; Russell H Swerdlow
Journal:  Redox Biol       Date:  2014-04-01       Impact factor: 11.799

8.  Screen for mitochondrial DNA copy number maintenance genes reveals essential role for ATP synthase.

Authors:  Atsushi Fukuoh; Giuseppe Cannino; Mike Gerards; Suzanne Buckley; Selena Kazancioglu; Filippo Scialo; Eero Lihavainen; Andre Ribeiro; Eric Dufour; Howard T Jacobs
Journal:  Mol Syst Biol       Date:  2014-06-21       Impact factor: 11.429

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.